View sample alerts with expert analyses from the inThought team.
September 10, 2020 Impact: Moderate Gemini Therapeutics enrolls first patients for its phase 2a ReGAtta study to evaluate the safety and efficacy of GEM-103 for the treatment of patients with GA secondary to dry AMD. The study will recruit up to 80 participants and will include both patients from the phase 1 study as well […]
September 1, 2020 Impact: Moderate Gilead has reached an exclusive licensing agreement for Jounce Therapeutic’s JTX-1811. JTX-1811 is a monoclonal antibody (mAb) that targets CCR8 to deplete immunosuppressive tumor-infiltrating T regulatory cells (Tregs). CCR8 is expressed by these Tregs and they are depleted by JTX-1811 treatment. JTX-1811 has yet to enter the clinic, an IND […]
August 25, 2020 Impact: Moderate Highlights Immunovant reported topline results for its Phase 2a ASCEND-MG trial of IMVT-1401, an SC anti-FcRN, in MG: Three arms were included (6 weeks treatment period with weekly dosing): 340 mg IMVT-1401 weekly (N=5), 680 mg IMVT-1401 weekly (N=5), and placebo (N=5). Targeted enrollment rate was 21 patients, but trial […]
August 20, 2020 Impact: Moderate Gilead and Tango will expand a 2018 agreement into a multi-year discovery, development, and commercialization collaboration of novel immune evasion therapies in oncology. The deal structure includes: $125M up-front payments and a $20M equity investment. Opt-in rights to up to 15 targets up to $410M per program in total payments […]
August 6, 2020 Impact: High Biogen and Denali Therapeutics announced an agreement to co-develop and co-commercialize Denali’s small molecule LRRK2 franchise for PD. Biogen receives the rights to opt into two programs, and rights of first negotiation for two other programs – both related to Denali’s blood-brain barrier technology, Transport Vehicle. Under terms of the […]
July 22, 2020 Impact: High GENFIT has officially terminated its pivotal RESOLVE-IT trial of elafibranor for the treatment of NASH with fibrosis after it failed an interim analysis back in May. The trial did not meet the predefined primary surrogate efficacy endpoint of NASH resolution without worsening of fibrosis in the ITT population of 1,070 […]